NCT04262466 2026-03-06
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Phase 1/2 Active not recruiting
Immunocore Ltd
BeOne Medicines
BeOne Medicines
Amgen
Ferring Ventures Limited
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Refnot-Pharm Ltd
Aduro Biotech, Inc.